Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.78 |
| ▸ | HTT | P42858 | 4/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.78 |
| ▸ | LMNA | P02545 | 4/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | MIF | P14174 | 5/20 | 0.58 |
| ▸ | CD74 | P04233 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17312297 | 0.90 | TSHR (0.63) | TSHRHTTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL17327966 | 0.89 | TSHR (0.80) | TSHRHTTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL16296741 | 0.89 | TSHR (0.63) | TSHRHTTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL16296890 | 0.83 | TSHR (0.80) | TSHRHTTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL17312321 | 0.82 | TSHR (0.74) | TSHRHTTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL18402541 | 0.82 | TSHR (0.65) | TSHRHTTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL18402582 | 0.80 | TSHR (0.56) | TSHRHTTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL17327970 | 0.80 | TSHR (0.65) | TSHRHTTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL18402538 | 0.80 | TSHR (0.62) | TSHRHTTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL17312335 | 0.77 | TSHR (0.59) | TSHRHTTSMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9549988-B2 | Pharmaceutical compounds targeted by MIF affinity-tethered moieties | RJS Biologics (US) | 2017-01-24 | — | — | US | disclosed |
| US-9549988-B2 | Pharmaceutical compounds targeted by MIF affinity-tethered moieties | RJS Biologics (US) | 2017-01-24 | — | — | US | disclosed |
| US-9549988-B2 | Pharmaceutical compounds targeted by MIF affinity-tethered moieties | RJS Biologics (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | RJS BIOLOGICS LLC | 2015-12-10 | — | — | US | disclosed |
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | RJS BIOLOGICS LLC | 2015-12-10 | — | — | US | disclosed |
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | RJS BIOLOGICS LLC | 2015-12-10 | — | — | US | disclosed |
| WO-2014200872-A9 | PHARMACEUTICAL COMPOUNDS TARGETED BY MIF AFFINITY-TETHERED MOIETIES | RJS BIOLOGICS LLC (US) | 2015-02-05 | — | — | WO | disclosed |
| WO-2014200872-A1 | PHARMACEUTICAL COMPOUNDS TARGETED BY MIF AFFINITY-TETHERED MOIETIES | RJS BIOLOGICS LLC (US) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | MIF, HMGB2, HMGB1 | TSHR 3054/4885HTT 1057/4885SMN1; SMN2 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.